IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients
Tsitol Genet. 2016 Sep-Oct;50(5):79-84.
[Article in
English,
Russian]
Abstract
The aim of this study was to examine association between IFNL4 gene ss469415590 and treatment efficiency in group of Ukrainian PEG-interferon/ribavirin-treated chronic hepatitis C patients. Study group consisted of 92 unrelated hepatitis C virus genotype 1 mono-infected patients: case group - 29 patients with late or absent virological response; control group - 63 patients with sustained virological response. Study material was genomic DNA. Genotyping was performed using amplification-refractory mutation system PCR. Statistical analysis was performed using GenePop and OpenEpi statistical packages. Obtained results show that ss469415590 ΔG/ΔG genotype is associated with poor virological response (OR = 3.62; CI 95%: 1.12-11.67) in PEG-interferon/ribavirin-treated chronic hepatitis C patients from Ukraine.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Biomarkers, Pharmacological / metabolism
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Gene Expression
-
Genotype
-
Hepacivirus / drug effects*
-
Hepacivirus / growth & development
-
Hepacivirus / immunology
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / genetics
-
Hepatitis C, Chronic / immunology
-
Hepatitis C, Chronic / virology
-
Humans
-
Interferon alpha-2 / therapeutic use*
-
Interferon-alpha / therapeutic use*
-
Interleukins / genetics*
-
Interleukins / immunology
-
Odds Ratio
-
Polyethylene Glycols / therapeutic use*
-
Polymorphism, Single Nucleotide
-
Predictive Value of Tests
-
Recombinant Proteins / therapeutic use
-
Ribavirin / therapeutic use*
-
Ukraine
-
Viral Load / drug effects
Substances
-
Antiviral Agents
-
Biomarkers, Pharmacological
-
IFNL4 protein, human
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukins
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b